熱門資訊> 正文
Horizon Space Acquisition II宣布与SL Bio达成业务合并协议
2025-05-12 20:54
- Horizon Space Acquisition II Corp. (NASDAQ:HSPT), a publicly traded special purpose acquisition company, and SL Bio, a clinical-stage biomedical company specialized in developing groundbreaking cellular and gene therapies for skin care and cancer recovery, said they have entered into a definitive business combination agreement.
- Upon completion of the business combination of HSPT and SL Bio and related transactions pursuant to the Business Combination Agreement, SL Science Holding Limited, a Cayman Islands exempted company newly formed for purposed of effecting the proposed transaction will be listed on Nasdaq.
- The proposed transactions are expected to close by late 2025.
- Upon completion of the transactions, PubCo will be led by CEO and Chairman, William Wang. Johnson Lau will serve as CFO and Ethan Shen will serve as Chief Technology Officer.
- Source: Press Release
More on Horizon Space Acquisition II Corp.
- Financial information for Horizon Space Acquisition II Corp.
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
